Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2023.2211764
Abstract: ABSTRACT Introduction Protein kinases play a crucial role in intracellular signaling pathways that lead to inflammation and cell proliferation. New understandings of the involvement of these metabolic pathways in the pathogenesis of psoriasis allowed the… read more here.
Keywords: deucravacitinib selective; inhibitor; selective tyrosine; moderate severe ... See more keywords
Computational Approaches for the Design of (Mutant-)Selective Tyrosine Kinase Inhibitors: State-of-the-Art and Future Prospects.
Sign Up to like & getrecommendations! Published in 2020 at "Current topics in medicinal chemistry"
DOI: 10.2174/1568026620666200502005853
Abstract: Kinases remain one of the major attractive therapeutic targets for a large number of indications such as cancer, rheumatoid arthritis, cardiac failure and many others. Design and development of kinase inhibitors (ATP-competitive, allosteric or covalent)… read more here.
Keywords: kinase inhibitors; computational approaches; kinase; selective tyrosine ... See more keywords
Apoptosis-related Proteins Are Altered by Selective Tyrosine Kinase Inhibitors and Everolimus in HPV-dependent SCC
Sign Up to like & getrecommendations! Published in 2020 at "AntiCancer Research"
DOI: 10.21873/anticanres.14639
Abstract: Background: Head and neck squamous cell cancer (HNSCC) affects the oral cavity and the pharynx. The aim of the study was to investigate the effects of selective tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib, nilotinib and… read more here.
Keywords: kinase inhibitors; selective tyrosine; scc; apoptosis related ... See more keywords